Group 1 - The vaccine ETF (159643) has risen over 1.7%, driven by both policy and technological advancements in the pharmaceutical industry [1] - The vaccine industry is expected to see a recovery or continued growth in key vaccine products such as PCV13, diphtheria vaccine, and MCV4, supported by improved channel inventory [1] - The blood products sector is projected to experience steady growth in plasma collection volume in 2024, contributing to future growth [1] Group 2 - The IO multi-antibody, ADC, and GLP-1 fields are witnessing continuous validation of Chinese assets, enhancing international competitiveness and driving rapid industry development [1] - National policies are encouraging the development of innovative drugs, further supporting the growth of the pharmaceutical sector [1] - The vaccine ETF tracks the vaccine biotechnology index (980015), which reflects the overall performance of listed companies involved in vaccine research, production, and related biotech services [1]